INT30206

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1985
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 19
Disease Relevance 10.03
Pain Relevance 5.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (ADA) aging (ADA) cytoplasm (ADA)
cytosol (ADA) extracellular space (ADA) cell adhesion (ADA)
Anatomy Link Frequency
immune system 3
brain 2
macrophage 1
Monocyte 1
CSF 1
ADA (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 422 100.00 Very High Very High Very High
adenocard 269 100.00 Very High Very High Very High
antidepressant 9 99.32 Very High Very High Very High
rheumatoid arthritis 43 98.20 Very High Very High Very High
Arthritis 10 97.64 Very High Very High Very High
spinal inflammation 4 97.04 Very High Very High Very High
Inflammation 47 96.90 Very High Very High Very High
Hyperalgesia 2 92.16 High High
Clonidine 2 92.00 High High
Angina 8 86.28 High High
Disease Link Frequency Relevance Heat
Disease 250 99.96 Very High Very High Very High
Graft Vs Host Disease 120 99.14 Very High Very High Very High
Fever 180 98.94 Very High Very High Very High
Severe Combined Immunodeficiency 5 98.68 Very High Very High Very High
Rheumatoid Arthritis 43 98.20 Very High Very High Very High
Seronegative Spondarthritis 4 98.04 Very High Very High Very High
Fistula 28 97.48 Very High Very High Very High
Low Back Pain 4 97.04 Very High Very High Very High
Mycobacterial Infection 27 96.92 Very High Very High Very High
INFLAMMATION 42 96.90 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, the results suggest that this effect was due to inhibition of adenosine deaminase rather than inhibition of nucleotide exchange as had previously been suggested.
Negative_regulation (inhibition) of adenosine deaminase associated with adenocard
1) Confidence 0.59 Published 1994 Journal Fundam Clin Pharmacol Section Abstract Doc Link 7875639 Disease Relevance 0.25 Pain Relevance 0.41
The selective inhibitor of adenosine deaminase erythro-9-(2-hydroxy-3-nonyl adenosine) exhibited the same profile of activity in the human red blood cell assay. pIC50 values for the four compounds named above were found to be 6.80 +/- 0.09, 6.95 +/- .03, 6.10 +/- 0.14 and 7.39 +/- 0.05 vs adenosine disapearance observed in the extracellular incubation medium respectively.
Negative_regulation (inhibitor) of adenosine deaminase in red blood cell associated with adenocard
2) Confidence 0.43 Published 1994 Journal Fundam Clin Pharmacol Section Abstract Doc Link 7875639 Disease Relevance 0.24 Pain Relevance 0.46
Children born with a life-threatening immune system disorder, severe combined immune deficiency (SCID), were cured after receiving gene therapy for replacement of their defective adenosine deaminase (ADA) gene.
Negative_regulation (defective) of ADA in immune system associated with adenocard and severe combined immunodeficiency
3) Confidence 0.42 Published 2003 Journal Expert Opin Biol Ther Section Abstract Doc Link 12718732 Disease Relevance 0.23 Pain Relevance 0.05
ADA deficiency is the major metabolic cause of severe combined immunodeficiency disease.31,32 ADA is important for the development of the immune system in humans.
Negative_regulation (deficiency) of ADA in immune system associated with severe combined immunodeficiency
4) Confidence 0.40 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.16 Pain Relevance 0.04
It seems to be associated with the differentiation of epithelial cells and monocytes and with neurotransmission.33 Monocyte/macrophage activation by intracellular infection and inflammatory diseases leads to the release of ADA and elevated levels in the serum.34 Monocyte involvement in CCHF has been well described.19 However, no studies have reported the ADA/XO levels in patients with CCHF.
Negative_regulation (reported) of ADA in macrophage associated with inflammation, fever, disease and infection
5) Confidence 0.40 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.49 Pain Relevance 0.05
Children born with a life-threatening immune system disorder, severe combined immune deficiency (SCID), were cured after receiving gene therapy for replacement of their defective adenosine deaminase (ADA) gene.
Negative_regulation (defective) of deaminase in immune system associated with adenocard and severe combined immunodeficiency
6) Confidence 0.37 Published 2003 Journal Expert Opin Biol Ther Section Abstract Doc Link 12718732 Disease Relevance 0.23 Pain Relevance 0.05
A total of 325 patients were randomized to receive ADA 160 mg at week 0 and 80 mg at week 2, or placebo at weeks 0 and 2 and followed through week 4.
Negative_regulation (receive) of ADA associated with adalimumab
7) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.43 Pain Relevance 0.38
ADA is available in more than 70 countries and is approved in the US and EU for treating patients with RA, psoriatic arthritis, and ankylosing spondylitis.
Negative_regulation (approved) of ADA associated with seronegative spondarthritis, spinal inflammation, rheumatoid arthritis, adalimumab and arthritis
8) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.69 Pain Relevance 0.72
She recovered by antibiotics for 45 days and ADA level in CSF was normalized.
Negative_regulation (level) of ADA in CSF
9) Confidence 0.16 Published 2009 Journal Rinsho Shinkeigaku Section Abstract Doc Link 19928691 Disease Relevance 0.83 Pain Relevance 0.16
The increase of basal lipolytic rate and the reversal of adrenaline action seen during caloric restriction could be mimicked by removal of endogenous adenosine using adenosine deaminase (1.6 microgram ml-1).
Negative_regulation (removal) of adenosine deaminase associated with adenocard
10) Confidence 0.15 Published 1985 Journal Eur. J. Clin. Invest. Section Abstract Doc Link 2859198 Disease Relevance 0.52 Pain Relevance 0.47
It seems to be associated with the differentiation of epithelial cells and monocytes and with neurotransmission.33 Monocyte/macrophage activation by intracellular infection and inflammatory diseases leads to the release of ADA and elevated levels in the serum.34 Monocyte involvement in CCHF has been well described.19 However, no studies have reported the ADA/XO levels in patients with CCHF.
Negative_regulation (reported) of ADA in Monocyte associated with inflammation, fever, disease and infection
11) Confidence 0.14 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2910858 Disease Relevance 1.49 Pain Relevance 0.05
However, the decrease in ADA activity in blood cells may be associate with the adenosine metabolism.
Negative_regulation (decrease) of ADA in blood cells associated with adenocard
12) Confidence 0.12 Published 1997 Journal Haematologia (Budap) Section Abstract Doc Link 9408766 Disease Relevance 0.50 Pain Relevance 0.53
The clinical value of PEGylation was first shown with PEG-adenosine deaminase (PEG-ADA, AdagenĀ®; Enzon Pharmaceuticals) [25], which has been used since 1990 as replacement therapy for immune deficiency due to inherited ADA deficiency.
Negative_regulation (deficiency) of ADA associated with adenocard
13) Confidence 0.10 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526556 Disease Relevance 0.50 Pain Relevance 0.12
Further studies on site-specific effectiveness of encapsulated ATP and adenosine on intestinal permeability changes are warranted.


Negative_regulation (effectiveness) of adenosine associated with adenocard
14) Confidence 0.04 Published 2007 Journal BMC Gastroenterol Section Body Doc Link PMC1913056 Disease Relevance 0 Pain Relevance 0.17
A fourth potential explanation of the ineffectiveness of ATP and adenosine in the present study could be relative insolubility of ATP and adenosine.
Negative_regulation (ineffectiveness) of adenosine associated with adenocard
15) Confidence 0.04 Published 2007 Journal BMC Gastroenterol Section Body Doc Link PMC1913056 Disease Relevance 0 Pain Relevance 0.25
Current antidepressant use may therefore interfere with effects of ATP/adenosine.
Negative_regulation (effects) of adenosine associated with adenocard and antidepressant
16) Confidence 0.04 Published 2007 Journal BMC Gastroenterol Section Body Doc Link PMC1913056 Disease Relevance 0.09 Pain Relevance 0.51
For example, of twenty-two heavily-treated patients with steroid-refractory acute GVHD treated with pentostatin (an irreversible inhibitor of adenosine-deaminase) on a phase I trial, seventeen had an objective response.
Negative_regulation (inhibitor) of adenosine-deaminase associated with adenocard and graft vs host disease
17) Confidence 0.04 Published 2007 Journal Orphanet J Rare Dis Section Body Doc Link PMC2018687 Disease Relevance 0.62 Pain Relevance 0.21
Biochemical analysis revealed that chronic treatment with PTZ significantly increased lipid peroxidation (malondialdehyde levels), nitrite (NO(2-) levels), adenosine deaminase (ADA) and total RNA levels and decreased catalase, reduced glutathione (GSH) levels in brain homogenates, and a depletion of adrenal ascorbic acid.
Negative_regulation (reduced) of deaminase in brain associated with adenocard
18) Confidence 0.01 Published 2007 Journal Fundam Clin Pharmacol Section Abstract Doc Link 18034659 Disease Relevance 0.38 Pain Relevance 0.50
Biochemical analysis revealed that chronic treatment with PTZ significantly increased lipid peroxidation (malondialdehyde levels), nitrite (NO(2-) levels), adenosine deaminase (ADA) and total RNA levels and decreased catalase, reduced glutathione (GSH) levels in brain homogenates, and a depletion of adrenal ascorbic acid.
Negative_regulation (decreased) of deaminase in brain associated with adenocard
19) Confidence 0.01 Published 2007 Journal Fundam Clin Pharmacol Section Abstract Doc Link 18034659 Disease Relevance 0.38 Pain Relevance 0.50

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox